Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111176 | 0.93 | EBP (0.47) | EBPSIGMAR1ESR1ESR2ACHE | |
| SCHEMBL7110645 | 0.84 | EBP (0.48) | EBPSIGMAR1ESR1ESR2ACHE | |
| SCHEMBL7113234 | 0.84 | EBP (0.45) | EBPSIGMAR1ACHEHRH3LTA4H | |
| SCHEMBL7111251 | 0.84 | EBP (0.53) | EBPSIGMAR1ESR1ESR2ACHE | |
| SCHEMBL7106831 | 0.81 | EBP (0.56) | EBPSIGMAR1ESR1ESR2ACHE | |
| SCHEMBL7111248 | 0.80 | EBP (0.53) | EBPSIGMAR1ESR1ESR2ACHE | |
| SCHEMBL7111796 | 0.79 | EBP (0.56) | EBPSIGMAR1ESR1ESR2HRH3 | |
| SCHEMBL7109918 | 0.78 | EBP (0.57) | EBPSIGMAR1ESR1ESR2HRH3 | |
| SCHEMBL7110644 | 0.77 | EBP (0.49) | EBPSIGMAR1ESR1ESR2ACHE | |
| SCHEMBL7113233 | 0.77 | EBP (0.46) | EBPSIGMAR1ESR1ESR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | EBP 1842/4885SIGMAR1 1661/4885ESR1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.